Novartis beefs up its data bank on Cosentyx’s durable effect on quality of life as well as scalp psoriasis
Novartis $NVS believes that it still has a long way to go in developing the blockbuster immunology market that it has on tap for Cosentyx. And their campaign to continue to expand on the $2 billion the pharma giant reaped from the drug last year is getting a boost today with the release of two new rounds of data on the durability of the drug in maintaining a better quality of life for patients and it’s efficacy in treating a particularly nettlesome form of psoriasis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.